EPI2ME 23.07-01 Release

By Chris Wright
Published in Software Releases
July 26, 2023
2 min read
EPI2ME 23.07-01 Release

Dear Nanopore Community,

We’re pleased to bring user experience updates to our EPI2ME desktop application (v5.1.0). For our Microsoft Windows users we have overhauled and simplified the installation process and we are now providing an EPI2ME WSL distribution. To improve feedback while your analysis is running, the application now reports progress bars for our workflows (Figure 1).

Other improvements include:

  • Enhanced handling of demonstration data when workflows are updated
  • Exporting of log information to assist issue reporting
  • Automatic checking for available updates to the application
  • Enabling more powerful workflow schemas

The EPI2ME software release is available from the downloads page

As a reminder we are currently soliciting early access users for the new cloud analysis functionality in the EPI2ME desktop application that will launch in 2024. You can register your interest here.

Workflow Progress
Figure 1. EPI2ME Workflow Progress dialog

We also have several workflow updates to which we would like to draw your attention. Highlights include wf-metagenomics (v2.4.1) which now provides antimicrobial gene identification, the option to use the SILVA.138 database to classify reads, memory management to solve issues with the PlusPF8 database, and finally, striking sunburst plots to display your data (Figure 2). wf-somatic-variation (v.0.3.0) now includes modified-base basecalling with information on differentially modified loci.

Sunburst Plot
Figure 2 - wf-metagenomics sunburst plot for interactively exploring taxonomic composition of a sample

Other workflow updates include:

  • wf-clone-validation (v0.4.0) - Now outputs a FASTQ and average quality scores of final assembly and reports any variants between an insert reference and assembly consensus. Also some parameter changes and documentation improvements.
  • wf-transcriptomes (v0.2.1) - Workflow has been updated to support only NCBI, Ensembl and Encode genome annotation files for differential gene expression. Also no longer requires a condition sheet.
  • wf-cas9 (v0.1.12) - Workflow has been updated to accept input files and directories that include spaces. 
  • wf-somatic-variation (v0.3.0) - Workflow has been updated to use nanomonsv (v.0.6.0) and now implements the call of modified bases and differentially modified loci and regions with (--mod.)
  • wf-metagenomics (v2.4.1) - Workflow has been updated to identify antimicrobial resistance genes using Abricate (through the flag --amr and --amr_db to choose among different databases). The workflow now supports memory-mapping large database files so these can be used on devices where the database size exceeds the available system memory. The well-known SILVA database is also available as an alternative database in both pipelines. Further, sunburst plots to explore taxonomic assignments have also been included in the report for the first time.
  • wf-single-cell (v0.2.6) - Workflow has been updated to fix the incorrect orientations of alignments when processing data from 10x Genomics 5-prime preparation methods.

We look forward to any feedback and welcome recommendations for workflows and EPI2ME features that could be included in future releases. See you in Singapore!


Tags

#notebooks#nextflow#workflows#releases#arm

Share

Chris Wright

Chris Wright

Senior Director, Customer Workflows

Related Posts

EPI2ME 24.02-01 Release
February 07, 2024
2 min

Quick Links

TutorialsWorkflowsOpen DataContact

Social Media

© 2020 - 2024 Oxford Nanopore Technologies plc. All rights reserved. Registered Office: Gosling Building, Edmund Halley Road, Oxford Science Park, OX4 4DQ, UK | Registered No. 05386273 | VAT No 336942382. Oxford Nanopore Technologies, the Wheel icon, EPI2ME, Flongle, GridION, Metrichor, MinION, MinIT, MinKNOW, Plongle, PromethION, SmidgION, Ubik and VolTRAX are registered trademarks of Oxford Nanopore Technologies plc in various countries. Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition.